Yarrow Bioscience, Inc. (formerly VYNE Therapeutics) reports that for the six months ended June 30, 2026 it generated $0.2 million in royalty revenue and incurred a net loss of $6.6 million, a substantial reduction from $14.4 million a year earlier, primarily due to sharply lower research and development spending as legacy programs were wound down ahead of its merger with Yarrow.
Cash and cash equivalents were $22.9 million and total assets $23.6 million, with liabilities of only $1.5 million, leaving stockholders’ equity at $22.1 million as of June 30, 2026 and no debt outstanding. The company completed a strategic merger with privately held Yarrow, changed its name, effected a 1‑for‑50 reverse stock split, declared a pre‑closing $17.3 million special cash dividend, and increased authorized common shares to support its new clinical‑stage focus on YB‑101 for Graves’ disease and thyroid eye disease. Management states that, giving effect to the merger, existing cash is expected to fund operations for at least 12 months from the financial statement issuance date, and Finacea royalty revenues are expected to cease after December 31, 2026 following LEO Pharma’s license termination.
Zhang Xiaofan filed Amendment No. 3 reporting beneficial ownership of common stock of Yarrow Bioscience, Inc.. The filing states beneficial ownership of 162,452 shares of common stock, representing 0.6% of the class. These shares are reported with both sole and shared voting and dispositive power.